BDTX BLACK DIAMOND THERAPEUTICS INC Product Launches 8-K Filing 2024 - Phase 2 Data Black Diamond Therapeutics announced initial Phase 2 data showing that their drug BDTX-1535 has a preliminary objective response rate of 42% in patients with recurrent EGFRm non-small cell lung cancer, with a favorable safety profile and encouraging durability of response.Get access to all SEC 8-K filings of the BLACK DIAMOND THERAPEUTICS INC